Gietl didn't leave. He's still here as well. This is similar to him holding the CEO position in both Availa and Cannagistics, which is now one and the same.
This looks like a potential partnership or holding. Their immune work is similar in the method of operation of what the fragmented peptides showed in the Immunazin product here as far as modulating the immune response.
In addition, cannabis extracts downregulate the expression of receptors for SARS-CoV-2. Furthermore, some cannabinoids have an immunomodulatory activity that can mitigate the uncontrolled inflammatory response known as the “cytokine storm”, which is a feature of the most severe COVID-19 patients.
Since cannabinoids have the potential to limit the severity and progression of COVID-19, Pascal tested compounds in a cell-based assay. We found that one of our lead cannabinoids inhibits SARS-CoV-2 growth on primate cells. Significantly, the potency of the cannabinoid in this assay was similar to that of Remdesivir, the only drug authorized by the FDA for emergency use in COVID-19 treatment. These initial observations have illuminated the path toward rapid validation of cannabinoids in additional cell-based assays, in animal models of the disease and, ultimately, in human clinical trials.
The company has already received a grant from the NIH, that's Fauci's Organization.
The other thing noted was their partnership with Sorce Technologies on developing this product. Sorce is a private ingredient manufacturer, just received 5 million in funding, and is right in line with the supply chain concept of Availa.
If these cannabinoids showed results equal to Remdesivir, I am wondering if adding fragmented peptides into the mix could increase the efficacy even beyond that.
Like I keep saying, A Fortune 500 CEO like Jim Morrison does not show up in an OTC stock for no reason. I think there is a whole lot to come.
CNGT!!
News 
Market Data 
Discover 
AI
